Arrowhead's new obesity-focused subsidiary set for early clinical entry
This article was originally published in Scrip
Executive Summary
Arrowhead Research has set up a new company to commercialise a platform technology for use in developing treatments for weight-loss and obesity-related metabolic conditions. Ablaris Therapeutics hopes to have a drug candidate in the clinic in 2011.